Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
CARxALL clinical trial approved to evaluate CAR-T technology for patients with T-cell leukemia subtype

CARxALL clinical trial approved to evaluate CAR-T technology for patients with T-cell leukemia subtype

Novel approach could pave the way for new treatments to prevent relapse in breast cancer patients

Novel approach could pave the way for new treatments to prevent relapse in breast cancer patients

Study shows positive effect of concentrating surgery for children with neuroblastoma

Study shows positive effect of concentrating surgery for children with neuroblastoma

Scientists uncover how FoxH1 factor binds to specific points in the genome

Scientists uncover how FoxH1 factor binds to specific points in the genome

Major treatment advance revealed for adults with newly diagnosed B lineage acute lymphoblastic leukemia

Major treatment advance revealed for adults with newly diagnosed B lineage acute lymphoblastic leukemia

Targeted therapies and novel drug combinations show promise for the treatment of multiple leukemias

Targeted therapies and novel drug combinations show promise for the treatment of multiple leukemias

Study: Only 30% of people with neuroendocrine tumors consider living longer as top priority

Study: Only 30% of people with neuroendocrine tumors consider living longer as top priority

Simplified treatment regimen results in dramatic decrease in early deaths from acute promyelocytic leukemia

Simplified treatment regimen results in dramatic decrease in early deaths from acute promyelocytic leukemia

GOSH delivers world-first base-edited cell therapy for a patient with relapsed T cell leukemia

GOSH delivers world-first base-edited cell therapy for a patient with relapsed T cell leukemia

Three-drug combination highly effective in patients with high-risk forms of chronic lymphocytic leukemia

Three-drug combination highly effective in patients with high-risk forms of chronic lymphocytic leukemia

Extra year of chemotherapy lowers the risk of cancer recurrence in children with Ikaros leukemia

Extra year of chemotherapy lowers the risk of cancer recurrence in children with Ikaros leukemia

Ongoing Phase I clinical trial demonstrates successful re-treatment with CAR T cell therapy

Ongoing Phase I clinical trial demonstrates successful re-treatment with CAR T cell therapy

Discovery of cellular uptake pathway for larger molecules can be harnessed to create new drugs

Discovery of cellular uptake pathway for larger molecules can be harnessed to create new drugs

Researchers develop a virtual molecular library of thousands of 'command sentences' for cells

Researchers develop a virtual molecular library of thousands of 'command sentences' for cells

The critical role of flow cytometry in CAR+ T-Cell trials

The critical role of flow cytometry in CAR+ T-Cell trials

Scientists discover new potential mechanism for vision loss

Scientists discover new potential mechanism for vision loss

Pediatric acute myeloid leukemia genetic subtypes with poor outcomes show increased inflammatory cytokine signaling

Pediatric acute myeloid leukemia genetic subtypes with poor outcomes show increased inflammatory cytokine signaling

Rogue killer T cells associated with leukemia drive autoimmune diseases

Rogue killer T cells associated with leukemia drive autoimmune diseases

CAR T therapy extends its reach beyond oncology

CAR T therapy extends its reach beyond oncology

Additional mRNA COVID vaccine doses could salvage antibody responses in blood cancer patients

Additional mRNA COVID vaccine doses could salvage antibody responses in blood cancer patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.